LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Carmine Therapeutics

Carmine Therapeutics is pioneering a powerful new class of genetic medicines based on red blood cell extracellular vesicles (RBCEVs), for the delivery of novel therapeutic modalities that include nucleic acids. Using RBCEVs, we are developing a non-viral , in vivo, re-dosable gene therapy, overcoming current limitations of viral based gene therapies like immunogenicity, small transgene capacity and manufacturing challenges.

  • Tenzin Gocha, PhD Director, Scientific and Business Operations
  • Hon-Ren Huang Senior Director of Biology